Capa.jpg

THE NEXT GENERATION OF CLINICAL RESEARCH IN LATIN AMERICA

HAVE AN IDEA? AT RARAS WE TRANSFORM IT INTO A PRODUCT. RARAS FROM BENCH TO BED-SIDE.

Raras CRO focuses on reducing the journey of healthcare companies to and from Latin America combining smart solutions and unmatched support managing your portfolio from pre-clinical to commercialization.

Product-Development.png

PRODUCT DEVELOPMENT

RARAS’ has developed
a launch platform that creates pharmaceutical and device assets to generate investor value in the shortest possible time.

 

LEARN MORE

Clinical-Research.png

CLINICAL
RESEARCH

From Phase I to Phase III our Team has a long- standing relationship with research sites and the most innovative recruitment strategies.

LEARN MORE

RWE.png

RWE & RWD

From patient journey, to treatment assessment and prescriptions we generate robust data for diverse applications including regulatory, safety, marketing and further product development.

 

LEARN MORE

 
 
Industry.jpg

INDUSTRY

We have gone to the remotest locations to collect plants to be used as raw materials for certain therapeutics, engaged local communities in fair-trade supply deals and delivered all phases up to the Phase III trials that led to registration for the same medicines. No other CRO can transform an idea into a product. We love transformation and our clients are passionate about the results.

RARAS incorporated CRC CRO business. Our legacy experience from CRC – Cardiovascular Research Center expands over 13 years.

Pharma2.png

Our Team has conducted over 240 projects in 9 countries in Latin America

 

RARAS CRO was born from the merger of EUGEN, the only CRO in Uruguay, and CRC the largest medical device CRO in Brazil. A full-service, modern, high-tech CRO, driving fast and competitive drug and device development, bridging the gap from innovation to patients. 
 

With extensive experience conducting research in Latin America our group of scientists holds solid expertise in applying international quality standards to regional specificities. 

LEARN MORE